The problem of variants of unknown significance , or VUS, is not a new one. Whether a change in DNA sequence actually has any effect in practice is a question that has been with genomic diagnostics since the first clinical test, for BRCA, became available in 1996. (See BioWorld Insight, Jan. 28, 2013.) Read More
Without a doubt, wet age-related macular degeneration (AMD) has been a lucrative market for companies. Regeneron Pharmaceuticals Inc. announced $1.2 billion in U.S. sales of Eylea (aflibercept) in the first half of 2015, and Roche AG posted CHF769 million (US$804 million) in U.S. sales of Lucentis (ranibizumab). Read More
